Paul Bisaro
Insider (Form 4 reporting owner): Director CIK 1237253Name as filed: Bisaro PaulIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 12 Mar 2019, bought $479K in 5 open-market purchases across 4 companies.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Amneal Pharmaceuticals AMRX | Executive Chairman | 12 Mar 2019 | 12 Mar 2019 | 1$203K | – |
| Zoetis ZTS | Director | 13 May 2026 | 13 May 2026 | 1$152K | – |
| TherapeuticsMD TXMD | Director | 4 Jun 2020 | 16 Aug 2021 | 2$96K | – |
| Myriad Genetics MYGN | Director | 14 May 2026 | 14 May 2026 | 1$28K | – |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After purchases | -29.9 pts5 trades, 20% above the sector | -25.0 pts5 trades, 20% above the sector | too few trades3 trades |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | 2 | $179K | – | – | $179K |
| 2021 | 1 | $40K | – | – | $40K |
| 2020 | 1 | $57K | – | – | $57K |
| 2019 | 1 | $203K | – | – | $203K |
Every trade
5, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 14 May 2026 | Myriad Genetics MYGN | Buy | 7,500 | $3.69 | $28K | No | Form 4filed 14 May 2026 |
| 13 May 2026 | Zoetis ZTS | Buy | 2,000 | $75.88 | $152K | No | Form 4filed 13 May 2026 |
| 16 Aug 2021 | TherapeuticsMD TXMD | Buy | 50,000 | $0.79 | $40K | Not stated | Form 4filed 18 Aug 2021 |
| 4 Jun 2020 | TherapeuticsMD TXMD | Buy | 50,000 | $1.14 | $57K | Not stated | Form 4filed 8 Jun 2020 |
| 12 Mar 2019 | Amneal Pharmaceuticals AMRX | Buy | 17,000 | $11.97 | $203K | Not stated | Form 4filed 12 Mar 2019 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.